Screening
description
Transcript of Screening
ScreeningPHIL THIRKELL
What is screening?
A process of identifying apparently healthy people who may be at risk of a disease or condition
Identify Apparently healthy Increased risk of a disease/condition
Give 4 screening programmes undertaken in the UK.
Antenatal screening Postnatal screening – hearing, heel prick, neuroblastoma Cervical smear Mammography Chlamydia screening Bowel Cancer – FOBT Prostate cancer Abdominal Aortic Aneurysm Depression – PHQ-9 questionnaire etc.
Criteria for a Screening Programme Wilson + Jungner criteria
1. Important health problem2. Treatment available3. Facilities available for diagnosis and treatment4. Latent stage of the condition5. Test available to detect the condition6. Test is acceptable to the population7. Natural history of the disease is known8. Policy of who gets treatment has been made9. Financially viable
10. Case-finding is a continual process, not just a one off
Neonatal screening
Which conditions are screened for with blood spot testing? Phenylketonuria Sickle cell disease Cystic fibrosis Congenital hypothyroidism Medium-chain acyl-CoA dehydrogenase deficiency
Antenatal Screening
What is a pregnant woman screened for? Pre-eclampsia Rhesus antigen status / blood group Anaemia Diabetes Syphilis Hepatitis B/C HIV
Anomaly Scan – USS between 18-21 weeks
What is an anomaly scan used for? Spina bifida Down’s syndrome Hydrocephalus Cleft lip/palate
Date the pregnancy Sex of the baby Multiple pregnancy Organ development
Abdominal wall
Test Outcomes
Diseased Non-Diseased
Test positive True Positive False Positive
Test negative False Negative True Negative
Sensitivity
The number of people who have the disease who get a positive test result True positive / (True positive + False Negative)
e.g. 50 people with known Rheumatoid Arthritis. RhF blood test is positive in 42 of the patients. Sensitivity is 84%
Specificity
The number of people who don’t have a disease who are correctly told they don’t have it True negatives / (True negatives + False positives)
E.g. 30 patients with no evidence of rheumatoid arthritis have a blood test for RhF. 2 patients have a positive result. Specificity = 93%
Positive Predictive Value
The number of people who have a positive test result who actually do have the disease True positives / (True positives/False positives)
e.g. 2500 PSA blood tests performed on men >65yr. 800 are raised above normal levels. Biopsy reveals that 95 of these have prostate cancer. PPV = 95/(95+800) = 11%
Negative Predictive Value
The number of people who have a negative test result who definitely don’t have the disease True negatives / (true negatives + false negatives)
e.g. 2500 PSA blood tests on men >65yrs. 1700 have normal PSA results. 20 of these turn out to currently have prostate cancer despite a normal PSA. 1680/ (20 + 1680) = 98.8%
Diseased Non-Diseased
Test positive True Positive False Positive
Positive Predictive Value
TP / (TP + FP)
Test negative False Negative True Negative
Negative Predictive Value
TN / (TN + FN)
Sensitivity
TP / (TP + FN)
Specificity
TN / (TN + FP)
Screening Bias
Healthy screenee Length time Lead time Overdiagosis
Healthy screenee
Proactive patients who turn up to screening opportunities take better care of themselves are less likely to have a positive result Less likely to smoke, drink too much, have low income More likely to exercise, eat healthily, attend healthcare at other times
Internal locus of control
Length time
Screening appears to improve prognosis because slow-forming conditions are detected and treated earlier than they would compared to waiting for symptoms to start
e.g. 500 slow forming and 500 fast forming cancers happen each year Slow forming – no symptoms and better prognosis Fast forming – obvious symptoms and poor prognosis
Screening can detect lots of slow forming, but not many fast cancers
Because slow has better prognosis, it appears that screening helps outcome, but actually just selects a high proportion of slow cancers
Lead time
A screening test diagnoses something earlier but has no impact on outcome Appears to increase survival time, but doesn’t
Screening detects a disease
Symptoms start
Death
Screened patients
Non-screened patients
Lead time
Overdiagnosis
Patients are diagnosed with a condition which isn’t going to affect their life expectance e.g. prostate cancer diagnosis in old men Get a PSA blood test done, high result but managing with symptoms ok Now told they have cancer – anxiety, health insurance etc.
A new blood test is developed for rheumatoid arthritis. What is the sensitivity, specificity, PPV and NPV?
Diseased Non-Diseased
New test positive 250 26
New test negative 3 150
Sensitivity = 250 / (250+3) = 98.8 % Specificity = 150 / (150+26) = 85.2 %
PPV = 250 / (250+26) = 90.5 %NPV =150 / (150 + 3) = 98 %